Minerva Neurosciences, Inc. annual report, FY2014

Minerva Neurosciences, Inc. — 2014 Form 10-K

Reporting period: Fiscal year ended December 31, 2014. The company is a clinical-stage biopharmaceutical developer; it had no approved products and generated no revenue. The 2013 comparison is not fully comparable because Sonkei’s results were included only after its November 2013 merger, while Mind-NRG was acquired in February 2014.

Financial results and liquidity

Metric	2014	2013
Revenue	$0	$0
Research and development expense	$42.9 million	$0.7 million
General and administrative expense	$12.0 million	$2.5 million
Operating loss	$54.9 million	$3.2 million
Net loss	$56.9 million	$3.3 million
Net loss per share, basic and diluted	$4.47	$0.78
Cash used in operating activities	$36.0 million	$2.2 million
Cash and cash equivalents at year-end	$18.5 million	$1.8 million

• Expenses substantially exceeded revenue, so operating and profit margins are not meaningful. The company reported a $74.7 million accumulated deficit at year-end.
• R&D expense rose mainly due to a $22.0 million MIN-202 license fee, $13.1 million of stock-based compensation, higher MIN-101 development costs, and MIN-202 program costs. G&A growth reflected compensation, professional fees, staffing, office and public-company costs.
• Year-end current assets were $19.3 million and current liabilities were $3.5 million. There was no material funded debt reported at December 31, 2014; convertible notes had converted to common stock in July 2014.
• In January 2015, the company drew $10 million under a term loan facility of up to $15 million. In March 2015, it raised approximately $28.8 million net in a private placement. Management said cash, available borrowing and those proceeds were expected to fund operations through the end of 2016; further capital would be needed for later development, including Phase III trials.

Material changes and business developments

• Minerva completed its IPO in July 2014, raising approximately $28.2 million net, and received additional private-placement proceeds. The resulting financing materially increased cash and outstanding shares.
• It acquired Mind-NRG and its MIN-301 program in February 2014 and entered a co-development and license agreement with Janssen for MIN-202. The $22.0 million upfront MIN-202 fee was expensed in 2014.
• MIN-101, the schizophrenia candidate, had completed Phase IIa; the company planned a 234-subject Phase IIb study in Europe, with enrollment expected in 2015 and topline results anticipated in the first half of 2016.
• MIN-117, for major depressive disorder, was planned for a 60-subject Phase IIa study in Europe beginning in the second quarter of 2015. The MTPC license required first patient enrollment by the end of April 2015, or an extension payment, to avoid possible termination.
• MIN-202, for primary and comorbid insomnia, was being co-developed with Janssen. Phase IIa primary-insomnia and Phase Ib comorbid-insomnia studies were expected to begin in mid-2015. Minerva’s European rights carry royalties to Janssen; it is entitled to royalties on Janssen sales outside Europe.
• MIN-301, for Parkinson’s disease, remained preclinical. An IND or European filing was expected in 2016, with Phase I to follow.

Outlook, risks and unusual items

• Management expected continued operating losses and negative operating cash flow while advancing the pipeline; no product revenue was expected unless candidates receive regulatory approval and are commercialized.
• Funding runway depends on the stated financing sources and spending plan. The company cautioned that clinical costs, timelines and capital needs could exceed expectations, and additional financing might not be available on acceptable terms.
• Clinical efficacy and safety remain unproven. MIN-101’s earlier Phase IIa trial was small and not powered for statistical significance, although some negative-symptom analyses were statistically significant. Earlier MIN-101 studies also reported cardiac events and QT/QTc prolongation, including discontinuation of one Phase I study at higher doses.
• Other key risks include regulatory delay or rejection, patient recruitment and retention, reliance on CROs and contract manufacturers, competition, patent protection, reimbursement, and dependence on MTPC and Janssen. Janssen can opt out of further MIN-202 development at specified milestones; Minerva must fund its agreed share of development costs.
• The January 2015 loan is secured by substantially all assets other than intellectual property, includes restrictive covenants and potential acceleration/default fees, and limits dividends. The March 2015 financing involved substantial share issuance and warrants, creating dilution risk.
• Stock-based compensation was a significant noncash expense, including approximately $10.5 million recognized when previously issued restricted shares became probable of vesting following the IPO. No goodwill or in-process R&D impairment was recorded for 2014.
• Management reported prior-year material weaknesses in financial reporting controls and said they had been remediated by year-end 2014; a significant deficiency concerning income-tax disclosure remained. Management concluded disclosure controls were effective at a reasonable-assurance level. The auditor issued an unqualified opinion on the financial statements, but did not audit internal-control effectiveness.
• The filing states that no legal proceeding was expected to have a material adverse effect and reports no off-balance-sheet arrangements.

Important facts for investors to verify

• Whether the MIN-101 Phase IIb trial enrolled on schedule and whether its results support advancement to pivotal studies.
• Whether MIN-117 met the MTPC enrollment deadline or required an extension payment, and whether the planned Phase IIa study proceeded.
• MIN-202 development progress, Janssen’s funding and opt-out decisions, and Minerva’s remaining cost obligations under the collaboration.
• Actual cash burn and remaining liquidity relative to management’s end-2016 runway estimate, including debt service, covenants and future financing needs.
• Whether the prior control deficiencies, particularly the income-tax disclosure deficiency, were fully resolved in subsequent filings.
• Clinical safety signals, regulatory feedback, trial recruitment, patent coverage and any impairment indicators affecting acquired R&D assets and goodwill.